The discovery of chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK)
gene in non‐small cell lung cancer (NSCLC) has stimulated renewed interest in …

The success of tyrosine kinase inhibitors (TKIs) in select patients with non–small-cell lung
cancer (NSCLC) has transformed management of the disease, placing new emphasis on …

Emerging efficacy data have led to the emergency use authorization or approval of COVID-19
vaccines in several countries worldwide. Most trials of COVID-19 vaccines excluded …

Background Patients with advanced squamous-cell non–small-cell lung cancer (NSCLC)
who have disease progression during or after first-line chemotherapy have limited treatment …

Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …

Background ALK gene rearrangement defines a new molecular subtype of non-small-cell
lung cancer (NSCLC). In a recent phase 1 clinical trial, the ALK tyrosine-kinase inhibitor (TKI) …

KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously
reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of …

Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint inhibitors
(ICIs) is characterized by durable responses and improved survival in a subset of patients…

Purpose: PD-1 inhibitors are established agents in the management of non–small cell lung
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine the …

… JF Gainor is consultant/advisory board member for Bristol-Myers Squibb, Genentech, Ariad,
Novartis, Merck, Clovis, Boehringher Ingelheim, Jounce Therapeutics, and Kyowa Hakko …